2026-04-13T07:18:15Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1259062025-12-05T12:05:36Zcom_2072_1057col_2072_478916col_2072_478917col_2072_478921

00925njm 22002777a 4500 dc Caniglia, Ellen C. author Cain, Lauren E. author Justice, Amy C. author Tate, Janet author Logan, Roger author Sabin, Caroline author Winston, Alan author Sighem, Ard van author Miró Meda, José M. (José María), 1956- author Podzamczer Palter, Daniel author Olson, Ashley D. author Arribas, José Ramón author Moreno Guillén, Santiago author Meyer, Laurence author Romero, Jorge del author Dabis, François author Bucher, Heiner C. author Wandeler, Gilles author Vourli, Georgia author Skoutelis, Athanasios author Lanoy, Emilie author Gasnault, Jacques author Costagliola, Dominique author Hernán, Miguel A. author HIV-CAUSAL Collaboration author 2018-11-08T12:53:56Z 2018-11-08T12:53:56Z 2014-06-06 2018-11-08T12:53:56Z Objective: The link between CNS penetration of antiretrovirals and AIDS-defining neurologic disorders remains largely unknown. Methods: HIV-infected, antiretroviral therapy-naive individuals in the HIV-CAUSAL Collaboration who started an antiretroviral regimen were classified according to the CNS Penetration Effectiveness (CPE) score of their initial regimen into low (,8), medium (8-9), or high (.9) CPE score. We estimated "intention-to-treat" hazard ratios of 4 neuroAIDS conditions for baseline regimens with high and medium CPE scores compared with regimens with a low score. We used inverse probability weighting to adjust for potential bias due to infrequent follow-up. Results: A total of 61,938 individuals were followed for a median (interquartile range) of 37 (18, 70) months. During follow-up, there were 235 cases of HIV dementia, 169 cases of toxoplasmosis, 128 cases of cryptococcal meningitis, and 141 cases of progressive multifocal leukoencephalopathy. The hazard ratio (95% confidence interval) for initiating a combined antiretroviral therapy regimen with a high vs low CPE score was 1.74 (1.15, 2.65) for HIV dementia, 0.90 (0.50, 1.62) for toxoplasmosis, 1.13 (0.61, 2.11) for cryptococcal meningitis, and 1.32 (0.71, 2.47) for progressive multifocal leukoencephalopathy. The respective hazard ratios (95% confidence intervals) for a medium vs low CPE score were 1.01 (0.73, 1.39), 0.80 (0.56, 1.15), 1.08 (0.73, 1.62), and 1.08 (0.73, 1.58). Conclusions: We estimated that initiation of a combined antiretroviral therapy regimen with a high CPE score increases the risk of HIV dementia, but not of other neuroAIDS conditions. Sida Antiretrovirals Manifestacions neurològiques de les malalties AIDS (Disease) Antiretroviral agents Neurologic manifestations of general diseases Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions